Molecular modelling of CYP2A enzymes: Application to metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)

Xenobiotica

Volumn 34, Issue 6, 2004, Pages 515-533

  Jalas, J R ^a   Seetharaman, M ^c   Hecht, S S ^a   Murphy, S E ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Molec Biol   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CYTOCHROME P450 2A; CYTOCHROME P450 2A13; CYTOCHROME P450 2A3; CYTOCHROME P450 2A4; CYTOCHROME P450 2A5; CYTOCHROME P450 2A6; CYTOCHROME P450 2C5; CYTOCHROME P450 ISOENZYME; NITROSAMINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CATALYST; COMPARATIVE STUDY; ENZYME ACTIVE SITE; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; HYDROPHOBICITY; HYDROXYLATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN FOLDING; RAT; SEQUENCE ALIGNMENT; STEADY STATE; STEREOCHEMISTRY;

AMINO ACID SEQUENCE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; HUMANS; KINETICS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NITROSAMINES; PROTEIN FOLDING; RATS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY; TOBACCO;

ANIMALIA; NICOTIANA TABACUM;

EID: 3242762279     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250410001713131     Document Type: Article

References (66)

1. AIDA, K., MOORE, R. and NEGISHI, M., 1994, Lack of the steroid 15a-hydroxylase gene (CYP2A-4) in wild mouse strain Mus spretus: rapid evolution of the P450 gene superfamily. Genomics, 19, 564-566.
2. BATHELT, C., SCHMID, R. D. and PLEISS, J., 2002, Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking. Journal of Molecular Modelling (Online), 8, 327-335.
3. BERENDSEN, H. J. C., POSTMA, J. P. M., GUNSTEREN, W. F., DINOLA, A. and HAAK, J. R., 1984, Molecular dynamics with coupling to an external bath. Journal of Chemistry and Physics, 81, 3684-3690.
4. CASE, D. A., PEARLMAN, D. A., CALDWELL, J. W., CHEATHAM, T. E., WANG, J., ROSS, W. S., SIMMERLING, C. L., DARDEN, T. A., MERZ, K. M., STANTON, R. V., CHENG, A. L., VINCENT, J. J., CROWLEY, M., TSUI, V., RADMER, R. J., GOHLKE, H., DUAN, Y., PITERA, J., MASSOVA, I., SEIBEL, G. L., SINGH, U. C., WEINER, P. K. and KOLLMAN, P. A., 2002, AMBER 7, University of San Francisco.
5. CHENNA, R., SUGAWARA, H., KOIKE, T., LOPEZ, R., GIBSON, T. J., HIGGINS, D. G. and THOMPSON, J. D., 2003, Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Research, 31, 3497-3500.
6. DE GROOT, M. J., ALEX, A. A. and JONES, B. C., 2002, Development of a combined protein and pharmacophore model for cytochrome P450 2C9. Journal of Medical Chemistry, 45, 1983-1993.
7. DING, X. and KAMINSKY, L. S., 2003, Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual Reviews in Pharmacology and Toxicology, 43, 149-173.
8. ESSMANN, U., PERERA, L., BERKOWITZ, M. L., DARDEN, T. and PEDERSEN, L. G., 1995, A smooth particle mesh Ewald method. Journal of Chemistry and Physics, 103, 8577-8593.
9. FELICIA, N. D., REKHA, G. K. and MURPHY, S. E., 2000, Characterization of cytochrome P450 2A4 and 2A5-catalysed 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) metabolism. Archives in Biochemistry and Biophysics, 384, 418-424.
10. GOROKHOV, A., NEGISHI, M., JOHNSON, E. F., PEDERSEN, L. C., PERERA, L., DARDEN, T. A. and PEDERSEN, L. G., 2003, Explicit water near the catalytic I helix Thr in the predicted solution structure of CYP2A4. Biophysics Journal, 84, 57-68.
11. GOTOH, O., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences 3016. Journal of Biological Chemistry, 267, 83-90.
12. GUO, Z., SMITH, T. J., ISHIZAKI, H. and YANG, C. S., 1991, Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytochrome P450IIB1 in a reconstituted system. Carcinogenesis (London), 12, 2277-2282.
13. HARRIS, D. and LOEW, G., 1995, Prediction of regiospecific hydroxylation of camphor analogs by cytochrome P450cam. Journal of the American Chemistry Society, 117, 2738-2746.
14. HE, X., SHEN, J., SUN, L., DING, X., LU, A. and HONG, J.-Y., 2003, American Association for Cancer Research National Meeting, Washington, DC, 11-15 July 2003.
15. HECHT, S. S., 1998, Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Research in Toxicology, 11, 559-603.
16. HECHT, S. S., 1999, Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute, 91, 1194-1210.
17. HECHT, S. S., 2002, Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncology, 3, 461-469.
18. HECHT, S. S., 2003, Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nature Reviews Cancer, 3, 733-744.
19. HONG, J. Y., DING, X., SMITH, T. J., COON, M. J. and YANG, C. S., 1992, Metabolism of 4-(methylnitrosammo)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen, by rabbit nasal microsomes and cytochrome P450s NMa and NMb. Carcinogenesis (London), 13, 2141-2144.
20. IWASAKI, M., DARDEN, T. A., PARKER, C. E., TOMER, K. B., PEDERSEN, L. G. and NEGISHI, M., 1994, Inherent versatility of P-450 oxygenase. Conferring dehydroepiandrosterone hydroxylase activity to P-450 2a-4 by a single amino acid mutation at position 117. Journal of Biological Chemistry, 269, 9079-9083.
21. IWASAKI, M., DARDEN, T. A., PEDERSEN, L. G. and NEGISHI, M., 1995a, Altering the regiospecificity of androstenedione hydroxylase activity in P450s 2A-4/5 by a mutation of the residue at position 481. Biochemistry, 34, 5054-5059.
22. IWASAKI, M., DARDEN, T. A., PEDERSEN, L. G., DAVIS, D. G., JUVONEN, R. O., SUEYOSHI, T. and NEGISHI, M., 1993a, Engineering mouse P450coh to a novel corticosterone 15alpha-hydroxylase and modeling steroid-binding orientation in the substrate pocket. Journal of Biological Chemistry, 268, 759-762.
23. IWASAKI, M., DAVIS, D. G., DARDEN, T. A., PEDERSEN, L. G. and NEGISHI, M., 1995b, Multiple steroid-binding orientations: alteration of regiospecificity of dehydroepiandrosterone 2- and 7-hydroxylase activities of cytochrome P-450 2A-5 by mutation of residue 209. Biochemistry Journal, 306, 29-33.
24. IWASAKI, M., LINDBERG, R. L. P., JUVONEN, R. O. and NEGISHI, M., 1993b, Site-directed mutagenesis of mouse steroid 7 α-hydroxylase (cytochrome P-4507α): role of residue-209 in determining steroid-cytochrome P-450 interaction. Biochemistry Journal, 291, 569-573.
25. JALAS, J. R., DING, X. and MURPHY, S. E., 2003a, Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metabolism and Disposition, 31, 1199-1202.
26. JALAS, J. R., MCINTEE, E. J., KENNEY, P. M., UPADHYAYA, P., PETERSON, L. A. and HECHT, S. S., 2003b, Stereospecific deuterium substitution attenuates the tumorigenicity and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Chemical Research in Toxicology, 16, 794-806.
27. JUVONEN, R. O., IWASAKI, M. and NEGISHI, M., 1991, Structural function of residue-209 in coumarin 7-hydroxylase (P450coh). Enzyme-kinetic studies and site-directed mutagenesis. Journal of Biological Chemistry, 266, 16431-16435.
28. JUVONEN, R. O., IWASAKI, M., SUEYOSHI, T. and NEGISHI, M., 1993, Structural alteration of mouse P450coh by mutation of glycine-207 to proline: spin equilibrium, enzyme kinetics, and heat sensitivity. Biochemistry Journal, 294, 31-34.
29. KUMAR, S., SCOTT, E. E., LIU, H. and HALPERT, J. R., 2003, A rational approach to re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of cytochrome P450 2C5. Journal of Biological Chemistry, 278, 17178-17184.
30. LEWIS, D. F. V., 1999, Homology modeling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. Experimental Toxicology and Pathology, 51, 369-374.
31. LEWIS, D. F. V., 2002a, Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica, 32, 305-323.
32. LEWIS, D. F. V., 2002b, Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template. Journal of Inorganic Biochemistry, 91, 502-514.
33. LEWIS, D. F. V., DICKINS, M., LAKE, B. G., EDDERSHAW, P. J., TARBIT, M. H. and GOLDFARB, P. S., 1999, Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology, 133, 1-33.
34. LINDBERG, R. L. P. and NEGISHI, M., 1989, Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature, 339, 632-634.
35. LIU, J., ERICKSEN, S. S., BESSPIATA, D., FISHER, C. W. and SZKLARZ, G. D., 2003, Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382. Drug Metabolism and Disposition, 31, 412-420.
36. MODI, S., SUTCLIFFE, M. J., PRIMROSE, W. U., LIAN, L. Y. and ROBERTS, G. C., 1996, The catalytic mechanism of cytochrome P450 BM3 involves a 6A movement of the bound substrate on reduction. Nature Structure in Biology, 3, 414-417.
37. MORRIS, G. M., GOODSELL, D. S., HALLIDAY, R. S., HUEY, R., HART, W. E., BELEW, R. K. and OLSON, A. J., 1998, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computers in Chemistry, 19, 1639-1662.
38. NEGISHI, M., IWASAKI, M., JUVENON, R. O. and AIDA, K., 1992, Alteration of the substrate specificity of mouse 2A P450s by the identity of residue-209: steroid-binding site and orientation. Journal of Steroids in Biochemistry and Molecular Biology, 43, 1031-1036.
39. NEGISHI, M., UNO, T., HONKAKOSKI, P., SUEYOSHI, T., DARDEN, T. A. and PEDERSEN, L. P., 1996. The roles of individual amino acids in altering substrate specificity of the P450 2A4/2A5 enzymes. Biochimie, 78, 685-694.
40. ORTIZ DE MONTELLANO, P. R. (1995) Oxygen activation and reactivity. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, (New York: Plenum), pp. 245-303.
41. PARK, J. Y. and HARRIS, D., 2003, Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. Journal of Medical Chemistry, 46, 1645-1660.
42. PATTEN, C. J., SMITH, T. J., MURPHY, S. E., WANG, M. H., LEE, J., TYNES, R. E., KOCH, P. and YANG, C. S., 1996, Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Archives in Biochemistry and Biophysics, 333, 127-138.
43. 6-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells. Chemical Research in Toxicology, 15, 165-169.
44. PELKONEN, P., LANG, M. A., NEGISHI, M., WILD, C. P. and JUVONEN, R. O., 1997, Interaction of aflatoxin B1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity. Chemical Research in Toxicology, 10, 85-90.
45. PERLMAN, D. A., CASE, D. A., CALDWELL, J. W., Ross, W. S., CHEATHAM, T. E., DEBOLT, S., FERGUSON, D. M., SEIBEL, G. and KOLLMAN, P. A., 1995, AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics, and free energy calculations to simulate the structural and energetic properties of molecules. Computers in Physics Communications, 91, 1-41.
46. PETERSON, L. A., MATHEW, R. and HECHT, S. S., 1991, Quantitation of microsomal alpha-hydroxylation of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Research, 51, 5495-5500.
47. PODUST, L. M., KIM, Y., ARASE, M., NEELY, B. A., BECK, B. J., BACH, H., SHERMAN, D. H., LAMB, D. C., KELLY, S. L. and WATERMAN, M. R., 2003, The 1.92-A structure of Streptomyces coelicolor A3(2) CYP154C1. A new monooxygenase that functionalizes macrolide ring systems. Journal of Biological Chemistry, 278, 12214-12221.
48. PODUST, L. M., POULOS, T. L. and WATERMAN, M. R., 2001, Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proceedings of the National Academy of Sciences, USA, 98, 3068-3073.
49. POULOS, T. L., CUPP-VICKERY, J. and LI, H. (1995) Structural studies on prokaryotic cytochromes P450. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry (New York: Plenum), pp. 125-150.
50. RYCKAERT, J. P., CICCOTTI, G. and BERENDSEN, H. J. C., 1977, Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. Journal of Computers in Physics, 23, 327-342.
51. SCHALK, M. and CROTEAU, R., 2000, A single amino acid substitution (F363I) converts the regiochemistry of the spearmint (-)-limonene hydroxylase from a C6- to a C3-hydroxylase. Proceedings of the National Academy of Sciences, USA, 97, 11948-11953.
52. SCOTT, E. E., HE, Y. A., WESTER, M. R., WHITE, M. A., CHIN, C. C., HALPERT, J. R., JOHNSON, E. F. and STOUT, C. D., 2003, An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution. Proceedings of the National Academy of Sciences, USA, 100, 13196-13201.
53. SMITH, T. J., GUO, Z., GUENGERICH, F. P. and YANG, C. S., 1996, Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis, 17, 809-813.
54. SU, T., BAO, Z., ZHANG, Q. Y., SMITH, T. J., HONG, J. Y. and DING, X., 2000, Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-l-butanone. Cancer Research, 60, 5074-5079.
55. UPADHYAYA, P., STURLA, S. J., TRETYAKOVA, N., ZIEGEL, R., VILLALTA, P. W., WANG, M. and HECHT, S. S., 2003, Identification of adducts produced by the reaction of 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanol with deoxyguanosine and DNA. Chemical Research in Toxicology, 16, 180-190.
56. VENHORST, J., TER LAAK, A. M., COMMANDEUR, J. N. M., FUNAE, Y., HIROI, T. and VERMEULEN, N. P. E., 2003, Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. Journal of Medical Chemistry, 46, 74-86.
57. VON WEYMARN, L. and MURPHY, S. E., 2003, Cytochrome P450CYP 2A13-catalysed coumarin metabolism, comparison to CYPP450 2A5 and CYP2A6. Xenobiotica, 33, 73-81.
58. VON WEYMARN, L. B. and MURPHY, S. E., 2001, Coumarin metabolism by rat esophageal microsomes and cytochrome P450 2A3. Chemical Research in Toxicology, 14, 1386-1392.
59. WANG, J., CIEPLAK, P. and KOLLMAN, P. A., 2000, How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? Journal of Computers in Chemistry, 21, 1049-1074.
60. WANG, M., CHENG, G., STURLA, S. J., SHI, Y., MCINTEE, E. J., VILLALTA, P. W., UPADHYAYA, P. and HECHT, S.S., 2003, Identification of adducts formed by pyridyloxobutylation of deoxyguanosine and DNA by 4-(acetoxymethymitrosammo)-1- (3-pyridyl)-1-butanone, a chemically activated form of tobacco-specific carcinogens. Chemical Research in Toxicology, 16, 616-626.
61. WESTER, M. R., JOHNSON, E. F., MARQUES-SOARES, C., DANSETTE, P. M., MANSUY, D. and STOUT, C. D., 2003a, Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. Biochemistry, 42, 6370-6379.
62. WESTER, M. R., JOHNSON, E. F., MARQUES-SOARES, C., DIJOLS, S., DANSETTE, P. M., MANSUY, D. and STOUT, C. D., 2003b, Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1. Ang. resolution: evidence for an induced fit model of substrate binding. Biochemistry, 42, 9335-9345.
63. WILLIAMS, P. A., COSME, J., SRIDHAR, V., JOHNSON, E. F. and MCREE, D. E., 2000, Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Molecular Cell, 5, 121-131.
64. WILLIAMS, P. A., COSME, J., WARD, A., ANGOVE, H. C., MATAK, V. D. and JHOTI, H., 2003, Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 424, 464-468.
65. XU, C., RAO, Y. S., XU, B., HOFFMANN, E., JONES, J., SELLERS, E. M. and TYNDALE, R. F., 2002, An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochemical and Biophysical Research Communications, 290, 318-324.
66. ZHANG, X., SU, T., ZHANG, Q. Y., GU, J., CAGGANA, M., LI, H. and DING, X., 2002, Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. Journal of Pharmacology and Experimental Therapeutics, 302, 416-423.